Tuberous Sclerosis Complex
Released: December 17, 2019
Defense Health Program
Department of Defense Tuberous Sclerosis Complex Research Program
Anticipated Funding Opportunities for Fiscal Year 2020 (FY20)
The Fiscal Year 2020 (FY20) Defense Appropriations Bill has not been signed into law. Although FY20 funds have not been appropriated for the Department of Defense Tuberous Sclerosis Research Program (TSCRP), the TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.
The FY20 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
Subject to the FY20 Congressional appropriation for TSCRP funding, FY20 TSCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.
Applications submitted to the FY20 TSCRP are encouraged to address one or more of the following Focus Areas:
- Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
- Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures
- Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological and behavioral interventions
- Advancing clinical trial readiness and optimizing clinical care through development of biomarkers and clinical outcome measures, patient selection and sample size determination, pharmacokinetic/pharmacodynamics (PK/PD) studies, and enhanced trial design
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Exploration - Hypothesis Development Award||Investigators at or above postdoctoral fellow (or equivalent)||
|Idea Development Award||
Independent investigators at or above the level of Assistant Professor (or equivalent); or
Independent investigator at or below the level of Assistant Professor (or equivalent); or Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC, thereby bringing his/her expertise to the field.
|Clinical Translational Research Award||Independent investigators at or above the level of Assistant Professor (or equivalent).||
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Tuesday, December 17, 2019